Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.07 USD
-0.07 (-1.36%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Syros Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 15 | 23 | 15 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 10 | 15 | 23 | 15 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 139 | 151 | 123 | 97 | 80 |
Income After Depreciation & Amortization | -129 | -136 | -99 | -82 | -78 |
Non-Operating Income | -30 | 45 | 17 | 0 | 2 |
Interest Expense | 5 | 4 | 4 | 2 | 0 |
Pretax Income | -165 | -95 | -87 | -84 | -75 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -165 | -95 | -87 | -84 | -75 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -165 | -95 | -87 | -84 | -75 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -126 | -132 | -96 | -79 | -75 |
Depreciation & Amortization (Cash Flow) | 3 | 4 | 4 | 3 | 3 |
Income After Depreciation & Amortization | -129 | -136 | -99 | -82 | -78 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.33 | 12.63 | 6.55 | 4.61 | 4.01 |
Diluted EPS Before Non-Recurring Items | -4.70 | -9.33 | -14.20 | -18.10 | -18.80 |
Diluted Net EPS (GAAP) | -5.81 | -7.49 | -13.80 | -18.20 | -18.80 |
Fiscal Year end for Syros Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.39 | 3.76 | 2.83 | 2.95 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.39 | 3.76 | 2.83 | 2.95 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 27.52 | 38.40 | 36.84 | 36.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -27.13 | -34.64 | -34.01 | -33.22 |
Non-Operating Income | NA | -35.92 | -4.20 | -0.98 | 10.64 |
Interest Expense | NA | 1.33 | 1.30 | 1.28 | 1.22 |
Pretax Income | NA | -64.38 | -40.14 | -36.26 | -23.79 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -64.38 | -40.14 | -36.26 | -23.79 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -64.38 | -40.14 | -36.26 | -23.79 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.54 | 27.99 | 27.91 | 27.84 |
Diluted EPS Before Non-Recurring Items | NA | -1.19 | -1.35 | -1.30 | -0.85 |
Diluted Net EPS (GAAP) | NA | -2.23 | -1.43 | -1.30 | -0.85 |